"If your company is a [billion-dollar powerhouse] and signs a 'hold harmless' agreement, you can get the biomaterials you need. But if you're a small start-up don't even bother asking. This is very bad for the biomaterials industry because it's usually the small companies that lead in innovation."

— Carl McMillin, PhD, a consultant for biomaterials discussing the difficulties smaller companies have in acquiring the necessary biomaterials to develop their products, "Start-ups less likely to get biomaterials than 'big guys'."